early T-cell precursor leukemia
GPTKB entity
Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:T-cell_acute_lymphoblastic_leukemia
|
| gptkbp:affects |
T-cells
|
| gptkbp:age |
gptkb:Person
young adults |
| gptkbp:associated_with |
genetic mutations
immune system dysfunction poor response to treatment extramedullary disease high white blood cell count lymphoblasts in blood relapse risk |
| gptkbp:clinical_trial |
ongoing studies
phase I trials phase II trials phase III trials |
| gptkbp:current_use |
gptkb:healthcare_organization
gptkb:T-cell_acute_lymphoblastic_leukemia |
| gptkbp:end_of_life |
low
|
| gptkbp:genetic_diversity |
gptkb:PTEN
FBX W7 NOTC H1 |
| https://www.w3.org/2000/01/rdf-schema#label |
early T-cell precursor leukemia
|
| gptkbp:occurs_in |
rare
|
| gptkbp:research_focus |
biomarkers
treatment protocols long-term effects treatment outcomes survival analysis genetic profiling |
| gptkbp:risk_factor |
environmental factors
age genetic predisposition |
| gptkbp:social_responsibility |
blood tests
clinical evaluation flow cytometry poor cytogenetic analysis bone marrow biopsy |
| gptkbp:symptoms |
gptkb:fandom
fatigue weight loss fever bleeding night sweats swollen lymph nodes infections easy bruising |
| gptkbp:treatment |
gptkb:vaccine
palliative care combination therapy supportive care radiation therapy chemotherapy targeted therapy clinical management stem cell transplant maintenance therapy novel agents experimental therapies |